GSK-3β Deficiency Improves Diabetes in Mice
Author Information
Author(s): Tanabe Katsuya, Liu Zhonghao, Patel Satish, Doble Bradley W, Li Lin, Cras-Méneur Corentin, Martinez Sara C, Welling Cris M, White Morris F, Bernal-Mizrachi Ernesto, Woodgett James R, Permutt M. Alan
Primary Institution: Washington University School of Medicine
Hypothesis
Does genetic deficiency of GSK-3β improve insulin sensitivity and β-cell mass in mouse models of insulin resistance?
Conclusion
Reducing GSK-3β activity in insulin-resistant mice preserves β-cell mass and prevents diabetes onset.
Supporting Evidence
- Mice lacking GSK-3β showed improved insulin sensitivity.
- Reduction of GSK-3β preserved β-cell mass in insulin-resistant mice.
- GSK-3β activity was found to be elevated in diabetic mouse models.
- Crossbreeding of specific mouse strains demonstrated the role of GSK-3β in diabetes.
- The study suggests GSK-3β inhibitors could be a potential treatment for diabetes.
Takeaway
Scientists found that when they reduced a specific protein called GSK-3β in mice, it helped keep their insulin-producing cells healthy and prevented diabetes.
Methodology
The study involved crossing different genetically modified mouse models to assess the effects of GSK-3β deficiency on insulin sensitivity and β-cell mass.
Participant Demographics
Mice models, specifically GSK-3β+/− and Irs2−/− strains.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website